Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer.

AIM The aim of this study was to produce a novel polyclonal antibody against extracellular domain of NGEP protein and explore its role in prognosis of prostate cancer. MATERIALS & METHODS Polyclonal antibodies against two peptides (NGEP-p1 and NGEP-p2) derived extracellular domains of NGEP were prepared and the intensity and distribution of NGEP expression analyzed in large series of prostate tissue specimens. RESULTS We found a significant inverse correlation between NGEP expression and prognostic features such as Gleason score, pathologic tumor stage and prostate-specific antigen level using anti-NGEP-p2 antibody. CONCLUSION The results indicate that the high level of expression could be associated with good prognosis in prostate cancer. However, additional studies are required to evaluate NGEP as an independent prognostic factor for prostate carcinoma.

[1]  Xiaobin Zhang,et al.  Detection of Prostate Stem Cell Antigen Expression in Human Prostate Cancer Using Quantum-Dot-Based Technology , 2012, Sensors.

[2]  S. Landas,et al.  Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues , 2006, World Journal of Surgery.

[3]  S. Reed,et al.  Prostein expression is highly restricted to normal and malignant prostate tissues , 2004, The Prostate.

[4]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  H. C. Hartzell,et al.  ANOs 3-7 in the anoctamin/Tmem16 Cl- channel family are intracellular proteins. , 2012, American journal of physiology. Cell physiology.

[6]  M. Merino,et al.  Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer , 2013, Cancer Immunology, Immunotherapy.

[7]  Byungkook Lee,et al.  Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. , 2008, Cancer research.

[8]  Sepideh Hamzehlou,et al.  Reduction of non-specific binding in immunoassays requiring long incubations , 2012, Scandinavian journal of clinical and laboratory investigation.

[9]  H. C. Hartzell,et al.  Anoctamin/TMEM16 family members are Ca2+‐activated Cl− channels , 2009, The Journal of physiology.

[10]  M. Asadi-lari,et al.  BRCA1 Protein Expression Level and CD44+Phenotype in Breast Cancer Patients , 2011, Cell journal.

[11]  I. Pastan,et al.  NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. , 2007, Cancer research.

[12]  C. Drake.  Prostate cancer as a model for tumour immunotherapy , 2010, Nature Reviews Immunology.

[13]  G. Netto.  Molecular diagnostics in urologic malignancies: a work in progress. , 2011, Archives of pathology & laboratory medicine.

[14]  J. Tímár,et al.  Genomics of prostate cancer: Is there anything to „translate”? , 2008, Pathology & Oncology Research.

[15]  Andrew N. Gray,et al.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization , 2009, The Prostate.

[16]  R. Karnes,et al.  Immunotherapy for prostate cancer. , 2006, Current pharmaceutical design.

[17]  Lars Egevad,et al.  A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. , 2012, European urology.

[18]  M. Mohsenzadegan,et al.  Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis , 2013, Cancer Immunology, Immunotherapy.

[19]  H. Zarour,et al.  Cancer immunotherapy: Progress and challenges in the clinical setting , 2011, European journal of immunology.

[20]  J. Epstein,et al.  Theranostic and prognostic biomarkers: genomic applications in urological malignancies. , 2010, Pathology.

[21]  M. Gleave,et al.  The ability of prostate‐specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume , 2012, BJU international.

[22]  K. Itoh,et al.  Vaccination of Cytotoxic T Lymphocyte-Directed Peptides Elicited and Spread Humoral and Th1-Type Immune Responses to Prostate-Specific Antigen Protein in a Prostate Cancer Patient , 2005, Journal of immunotherapy.

[23]  O. Kallioniemi,et al.  Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins , 2011, Oncotarget.

[24]  James L. Gulley,et al.  New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy , 2009, Cancer Immunology, Immunotherapy.

[25]  R. Eeles,et al.  The role of genetic markers in the management of prostate cancer. , 2012, European urology.

[26]  Byungkook Lee,et al.  NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  I. Ellis,et al.  Expression of the stress‐related MHC class I chain‐related protein MICA is an indicator of good prognosis in colorectal cancer patients , 2006, International journal of cancer.